Author

Daisuke Honma

Daiichi-Sankyo (Japan)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Albert Fliss· 1 shared Avery R. ChildressiD· 1 shared Bin HuangiD· 1 shared Christian M. GosseriD· 1 shared Christine F. BrainsoniD· 1 shared Daniel R. PlaugheriD· 1 shared Dave-Preston I. Esoe· 1 shared Ellen J. BeswickiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Albert Fliss

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming

Avery R. Childress, Dave-Preston I. Esoe, Xiulong Song, Christian M. Gosser, Yindan Lin, Daniel R. Plaugher, Tanner J. DuCote, Kassandra J. Naughton, Erika M. Skaggs, Harrison Yang, Ryan A. Goettl, Jinpeng Liu, Zhonglin Hao, Albert Fliss, Daisuke Honma, , Christine F. Brainson

This study shows that EZH1/2 inhibition with valemetostat enhances anti-PD1 immunotherapy in lung squamous cell carcinoma by increasing MHC Class II and reprogramming neutrophils.

bioRxiv · Aug 1, 2026 · PreprintCancer Biology